Apogee Therapeutics, Inc. Operating Income
Apogee Therapeutics, Inc. (APGE) reported Operating Income of -$96.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- Apogee Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$96.00M.
- Apogee Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$82.77M.
- Apogee Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$78.06M.
- Apogee Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$71.28M.
- Apogee Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$285.60M.
- Apogee Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$216.87M.
- Apogee Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$93.00M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 5 month | Operating Income (Loss) 6 month | Operating Income (Loss) 8 month | Operating Income (Loss) 9 month | Operating Income (Loss) 11 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$96.00M 10-Q · filed 2026-08-10 | -$178.78M 10-Q · filed 2026-08-10 | -$256.83M derived: sum of 3 quarters · filed 2026-08-10 | -$328.11M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | -$82.77M 10-Q · filed 2026-05-11 | -$160.83M derived: sum of 2 quarters · filed 2026-05-11 | -$232.11M derived: sum of 3 quarters · filed 2026-05-11 | -$305.27M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | -$78.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$149.33M derived: sum of 2 quarters · filed 2026-03-02 | -$222.50M derived: sum of 3 quarters · filed 2026-08-10 | -$285.60M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | -$71.28M 10-Q · filed 2025-11-10 | -$144.44M derived: sum of 2 quarters · filed 2026-08-10 | -$207.54M 10-Q · filed 2025-11-10 | -$283.42M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | -$73.17M 10-Q · filed 2026-08-10 | -$136.26M 10-Q · filed 2026-08-10 | -$212.14M derived: sum of 3 quarters · filed 2026-08-10 | -$270.83M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | -$63.10M 10-Q · filed 2026-05-11 | -$138.98M derived: sum of 2 quarters · filed 2026-05-11 | -$197.66M derived: sum of 3 quarters · filed 2026-05-11 | -$241.78M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | -$75.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$134.57M derived: sum of 2 quarters · filed 2026-03-02 | -$178.69M derived: sum of 3 quarters · filed 2026-03-02 | -$216.87M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$58.69M 10-Q · filed 2025-11-10 | -$102.81M derived: sum of 2 quarters · filed 2025-11-10 | -$140.99M 10-Q · filed 2025-11-10 | -$178.14M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | -$44.12M 10-Q · filed 2025-08-11 | -$82.30M 10-Q · filed 2025-08-11 | -$119.46M derived: sum of 3 quarters · filed 2026-03-02 | -$143.76M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | -$38.18M 10-Q · filed 2025-05-12 | -$75.34M derived: sum of 2 quarters · filed 2026-03-02 | -$99.64M derived: sum of 3 quarters · filed 2026-03-02 | -$118.53M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | -$37.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$61.46M derived: sum of 2 quarters · filed 2026-03-02 | -$80.34M derived: sum of 3 quarters · filed 2026-03-02 | -$93.00M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$24.30M 10-Q · filed 2024-11-12 | -$43.19M derived: sum of 2 quarters · filed 2024-11-12 | -$55.85M 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$18.89M 10-Q · filed 2024-08-12 | -$31.54M 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | -$12.66M 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | -$30.73M 10-K · filed 2024-03-05 | ||||||
| 2022-09-30 | -$10.51M 10-Q · filed 2023-11-13 | -$12.32M derived: sum of 2 quarters · filed 2023-11-13 | -$16.63M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$1.82M 10-Q · filed 2023-08-28 | -$6.12M 10-Q · filed 2023-08-28 |